Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: RGETNE national NEN Registry comprises 74 hospitals from all regions of Spain.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Garcia Carbonero R, Jimenez-Fonseca P, Benavent M, Alonso V, Crespo G,
Keywords: G3 NEN, epidemiology, survival, patterns of care, response to chemotherapy,
Introduction: RGETNE national NEN Registry comprises 74 hospitals from all regions of Spain.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Garcia Carbonero R, Jimenez-Fonseca P, Benavent M, Alonso V, Alonso T,
Keywords: GEP-NEN, tumor registry, survival, prognosis, epidemiology,
Introduction: Adrenocortical carcinoma (ACC) in adults is a rare tumor (incidence 0.7-2/1000000/year). Median overall survival is 3-4 years and five-year survival is 0-28% in metastatic disease. The only curative therapy is complete surgical resection, plus adjuvant therapy depending on poor prognostic factors (ENSAT stage III, R1 resection or Ki67>10%). Both recurrent oligometastatic disease and patients who respond to systemic treatment (ST), a radical approach with surgery or local therapy (LT) may be treatment options.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Morales Herrero R, Herrero Rivera D, Santos Fernández P, Benavent M,
Keywords: ACC, chemotherapy, mitotane, local therapy,
Introduction: Previously our group showed the potential use of a score based on MGMT, NDRG-1 and PHLDA-3 immunohistochemistry (IHC) expression as predictor of outcome in operated PanNET (Viúdez et al. Oncotarget 2016).
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Viudez A
Authors: Viudez A, Crespo G, Gómez-Dorronsoro M, Benavent M, Hernando J,
Keywords: biomarker, PHLDA3, MGMT, IHC, NDRG1, CAPTEM, everolimus,
Introduction: MEN1, DAXX, ATRX, and PI3K/AKT/mTOR pathway genes are frequently mutated in pNETs. Sunitinib is approved and widely used in the metastatic setting but unfortunately, no validated predictive biomarker has been identified to guide therapy yet. The SUNEVO phase II trial of the Spanish Task Force Group for Neuroendocrine and Endocrine Tumours (GETNE) trial combined the pro-drug of EVO under SUN-induced hypoxic conditions.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Santos M, Lanillos J, Lopez C, Alonso Gordoa T, Benavent M,
Keywords: pancreatic, neuroendocrine, mutations, correlation,